Stimatix, which makes products for colostomy management, is controlled by German healthcare company B. Braun Group, which is “refocusing” aspects of its product portfolio.
To date, Trendlines has been paid some US$2.7 million in dividends and sales of assets of Stimatix.
The write-off was first announced on July 14.
Trendlines is expected to report its results on Aug 10.
See also: Thakral’s 1QFY2026 adjusted attributable profit more than doubles y-o-y to $3.3 mil
Trendlines’ SGX quoted shares last traded at 9.3 cents.
Scroll to continue
